N. Anthony Coles, Director at Cerevel Therapeutics Holdings, Inc. (CERE), sold 50,000 shares at $42.33 ($2.1M) on 2024-04-01, disclosed to the SEC on 2024-04-03.
Scheduled sale ($2.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-04 | $4.1M | — | Filing → |